Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[Q]: Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy. These range from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease. The successful development of imatinib as a therapeutic agent for CML can be attributed directly to decades of scientific discoveries. These discoveries determined that the BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib, with imatinib significantly improving the long-term survival of patients with CML. Continuing in this tradition of scientific discoveries leading to improved therapies, the understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance. Continued studies of hematologic malignancies will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.
[A]: What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?


[Q]: A house of cards? Sounds unbelievable, doesn't it? Not if the architect is 31-year-old Bryan Berg. He's made a career out of building fantastic card houses, stadiums, capitols, castles -- and the world's tallest card tower. How does he do it? Bryan's structures are amazing because they are made entirely of perfectly balanced, freestanding playing cards. He never uses glue, tape, or anything else to hold the cards together. Nor does he fold the cards. He's discovered another way to make a strong house of cards, using a trick from nature. To make plants strong, nature builds them with cells that have tough walls. Rows and rows of these cells form a grid that helps leaves and stems keep their shape. Bees use the same kind of repeating pattern to create strong honeycombs, where they live and store honey. Bryan designs similar grids, using cards to create a repeating pattern of cells. He begins with a single cell made by balancing four cards against one another to form a box. Then he repeats the cell over and over, expanding outward to form the grid, which makes a good foundation for a strong card structure. The larger the grid, the more weight it can carry. Sometimes Bryan uses several cards, instead of just one, to construct the cell walls, making the grid even stronger. The trick, he tells kids when he speaks in classrooms, is to place your cards as tightly together as possible when laying out your grid, making sure the cards are not leaning at all. After building this solid base, Bryan lays cards across the top to make the floor for the next "story" of the building. He may add towers, columns, steeples, or domes. Using the principle of repeating cells, Bryan builds structures of amazing strength. In the Cards Not surprisingly, Bryan has always been interested in building things. Growing up on a "big, old farm" in rural Iowa, he had plenty of room to play. "We were in the middle of nowhere," Bryan remembers, "with lots of space to do whatever we wanted. I was always making something, using things like sticks or bales of hay." Bryan's grandfather taught him how to stack cards. Bryan's two interests -- building and card stacking -- soon combined. But stacking in his family's farmhouse was challenging. "Our old house had wood floors that weren't all level," he reports. "And they weren't very firm. When people walked around, it was like 'earthquake action.' It was a challenge to build something that wouldn't fall down immediately." Bryan constructed tower after tower; he went through a lot of trial and error before he built anything taller than himself. When he placed a few decks of cards on top of his grid, he discovered how strong it was. Bryan's towers began to grow taller. How Tall Is Too Tall? Bryan's first Guinness World Record for the world's tallest card tower came in the spring of 1992, when he was in high school. Learning that the world record was 12 feet 10 inches, Bryan built a slim tower that topped out at 14 feet 6 inches. Done as a project for his geometry class, it took him 40 hours and 208 decks of cards. Since then he's gone on to win world records for even taller buildings. His latest winner measured 25 feet 3.5 inches and used about 2,400 decks of cards. _ Why don't these towers fall down? The key is in a good solid base, a repeating pattern of stories, and a tapering top. Bryan likes to point out how card buildings resemble real ones. They are built cell by cell, story by story. The separate parts make one strong whole. The heavier the building, the stronger and more stable it is. But the weight can't all be at the top. After spending so much time building something so cool, Bryan admits it's sometimes painful to see his structures destroyed. But he compares his work to the building of a sandcastle or an ice sculpture.
[A]: What was Bryan's first world record?


[Q]: In the last few years, several tyrosine kinase inhibitors (TKIs) have been synthesized and become available for preclinical studies and clinical trials. This article summarizes recent achievements in the mechanism of action, pharmacological properties, and clinical activity and toxicity, as well as the emerging role of TKIs in lymphoid malignancies, allergic diseases, and autoimmune disorders. A literature review was conducted of the MEDLINE database PubMed for articles in English. Publications from 2000 through January 2012 were scrutinized. The search terms used were Bruton's tyrosine kinase (Btk) inhibitors, PCI-32765, GDC-0834, LFM-A13, AVL-101, AVL-292, spleen tyrosine kinase (Syk) inhibitors, R343, R406, R112, R788, fostamatinib, BAY-61-3606, C-61, piceatannol, Lyn, imatinib, nilotinib, bafetinib, dasatinib, GDC-0834, PP2, SU6656 in conjunction with lymphoid malignancy, NHL, CLL, autoimmune disease, allergic disease, asthma, and rheumatoid arthritis. Conference proceedings from the previous 5 years of the American Society of Hematology, European Hematology Association, American Society of Clinical Oncology, and ACR/ARHP Annual Scientific Meetings were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. The use of TKIs, especially inhibitors of Btk, Syk, and Lyn, is a promising new strategy for targeted treatment of B-cell lymphoid malignancies, autoimmune disorders and allergic diseases. However, definitive data from ongoing and future clinical trials will aid in better defining the status of TKIs in the treatment of these disorders.
[A]:
Which enzyme is inhibited by a drug fostamatinib?